VERPLAS LIMITED
Company number 02033296 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: VERPLAS LIMITED
1. Financial Health Score: A-
Explanation: Verplas Limited is in robust financial health, exhibiting strong structural integrity and consistent profitability. The slight downgrade from a perfect score is due to mild symptoms of macroeconomic fatigue—specifically, a marginal decline in turnover and pre-tax profits reflecting the broader housing market slowdown. However, the company's underlying constitution is highly resilient, supported by a stable gross margin and the protective "immune system" of its parent company, Indutrade UK Limited.
2. Key Vital Signs
- Revenue (The Pulse): £13.21 million (2023)
- Interpretation: The patient's pulse remains strong, though it slowed slightly by 1.7% compared to 2022 (£13.44 million). This mild arrhythmia is not a sign of internal organ failure, but rather a physiological response to the external environment—the new build housing market, which suffered a 25-35% decline. Outperforming the wider market indicates a healthy, resilient constitution.
- Profit Before Tax (Blood Pressure): £1.23 million (2023)
- Interpretation: Blood pressure is slightly down from £1.49 million in 2022, representing a healthy but slightly reduced flow of oxygen (profit) through the body. This compression is largely attributed to cost inflation, specifically the 10% increase in the Living Wage over two years, which the company is absorbing while maintaining pricing.
- Gross Margin (Cholesterol Levels): 34% (2023)
- Interpretation: Maintaining the exact same gross margin as the previous year (34%) is an excellent sign. It shows the company is successfully passing on cost increases to customers without clogging the arteries—meaning sales volumes and pricing power remain intact.
- Net Assets (Skeletal Strength): £3.48 million (2023)
- Interpretation: The bones are getting stronger. Net assets grew from £3.38 million in 2022 to £3.48 million in 2023, despite the payout of a hefty £800,000 dividend to the parent company. This indicates the business is generating healthy bone mass (retained earnings) to support future growth.
- Cash (Hydration Levels): £67,323 (2023)
- Interpretation: At first glance, this looks like severe dehydration compared to the £108,508 held in 2017. However, this is a benign anomaly. The company participates in the Indutrade UK cash pool, meaning its "bloodstream" is connected to a larger circulatory system. The low standalone cash balance simply means excess fluids are being efficiently centralized rather than stagnating.
3. Diagnosis
Overall Condition: Robust, with mild macroeconomic fatigue.
The financial data reveals a business in fundamentally good health. The drop in turnover and pre-tax profit are surface-level symptoms of a challenging economic climate—specifically, the sharp contraction in the UK new build housing market. Importantly, the company has avoided the more severe illnesses affecting the construction sector by maintaining its 34% gross margin and growing its market share.
The low cash reserves are not a symptom of financial anemia; rather, they are the result of a deliberate centralization strategy via the Indutrade UK cash pool, which acts as a safety net and efficient fluid management system. Furthermore, the £800,000 dividend paid to the parent in April 2023 is a clear sign that the patient is generating surplus energy and successfully nourishing its parent group. The company’s focus on sustainability and Indoor Air Quality (IAQ) aligns well with long-term regulatory trends, giving it a strong immune defense against future market shifts.
4. Recommendations
To maintain and improve financial wellness, the following preventative and proactive measures are recommended:
- Cost Inflation Management (Diet and Exercise): The 10% Living Wage increase over two years is putting pressure on the arteries. Continue to focus on productivity and energy efficiency investments to metabolize these increased costs without having to raise prices to dangerous levels that might drive away customers.
- Diversification of Revenue Streams (Cross-Training): With the new build housing market down significantly, accelerate the push into untapped geographic regions and retrofit markets. Relying too heavily on one sector makes the patient susceptible to cyclical fevers.
- Sustainability as a Revenue Driver (Vitamin Supplements): The commitment to 100% recycled materials and renewable electricity is commendable, but it currently comes with "associated cost increases." Work on turning these sustainable practices into a premium pricing advantage rather than just a cost burden, transforming vitamins into a source of extra energy.
- Cash Flow Monitoring (Regular Check-ups): While the Indutrade cash pool provides excellent systemic support, continue to monitor trade debtors carefully. In a slowing market, the risk of late payments (blocked arteries) increases, so maintain strict credit policies to keep the localized cash flow circulating smoothly.